Optimizing Treatment Sequencing for Advanced/Metastatic Renal Cell Carcinoma
Optimizing Treatment Sequencing for Advanced/Metastatic Renal Cell Carcinoma is organized by Prime Education, LLC.
Release Date: April 26, 2023
Expiration Date: April 25, 2024
Description:
Novel therapies are poised to improve outcomes for patients with advanced/metastatic renal cell carcinoma (RCC). Join us for the second (of four) on-demand Learning Lab activity in this series for expert discussion on individualizing treatment decision-making based on risk stratification and patient-specific factors, and strategies for treatment sequencing after first-line therapy.
This activity is part of a series; case managers must complete all 4 activities in this Learning Lab before reporting credit to the Commission for Case Manager Certification using the activity code and approval number issued upon completion.
Agenda:
• Overview of Evidence-Based Guideline Recommendations for Creating Individualized, Patient-Centered Treatment Plans Based on Risk Stratification, and Disease-, Treatment-, and Patient-Specific Factors
• Expert Strategies for Sequencing of Therapies After First-Line Treatment
Learning Objectives:
• Differentiate available and emerging therapies for advanced renal cell carcinoma (RCC) based on mechanism of action, indication, placement in treatment, safety, and efficacy
• Apply current evidence to individualize treatment decision-making and sequencing of therapies for patients with advanced/metastatic RCC.